A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3

With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late diagnosis and rare actionable molecular alterations,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Christelle de la Fouchardière, Pia Gamradt, Sylvie Chabaud, Maxime Raddaz, Ellen Blanc, Olivier Msika, Isabelle Treilleux, Sophie Bachy, Anne Cattey-Javouhey, Pierre Guibert, Matthieu Sarabi, Pauline Rochefort, Pamela Funk-Debleds, Clélia Coutzac, Isabelle Ray-Coquard, Patrice Peyrat, Pierre Meeus, Michel Rivoire, Aurélien Dupré, Ana Hennino
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2022-04-01
Colecção:Journal of Personalized Medicine
Assuntos:
pancreatic adenocarcinoma
pancreatic cancer
BIGHPANC
TGFbeta
immune checkpoint inhibitors
prognostic analysis
Acesso em linha:https://www.mdpi.com/2075-4426/12/4/623
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados